ArticleDiagnostics (Basel, Switzerland)2020
Budget Impact Analysis of
Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.
- Budget impact models for lung cancer interventions: A systematic literature review.Journal of managed care & specialty pharmacy · 2024Pooled it
- Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review.PharmacoEconomics · 2023Pooled it
- A CT imaging-based deep learning model for predicting EGFR and KRAS mutations in non-small cell lung cancer: toward personalized treatment approaches.Translational lung cancer research · 2026Article
- Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC.Therapeutic advances in medical oncology · 2024Article
- Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment.Ontario health technology assessment series · 2024Article
- A Hybrid Algorithm of ML and XAI to Prevent Breast Cancer: A Strategy to Support Decision Making.Cancers · 2023Article
- Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.ESMO open · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the European Union, Greece has the highest incidence of lung cancer among people under 45 years of age. Epidermal growth factor receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.